Skip to main content


Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Fig. 4

Treatment outcomes by gender and treatment regimen. The 5-year overall survival (a), event-free survival (b), and cumulative incidence of relapse (c) by gender and treatment arm. Significant differences (p < 0.05) were observed in overall survival with inferior outcome observed in female patients treated with Arm B (F, B) and Arm C (F, C) vs. male patients treated with the same (M, B and M, C) regimens. In contrast, female vs. male patients treated with the less intensive regimen Arm A (F, A vs. M, A) had similar overall survival outcome

Back to article page